Table 2 Clinicopathological characteristics of patient samples and expression of FLOT2 in breast cancer patients and correlation between FLOT2 expression and clinicopathological characteristics of breast cancer patients

Age(y)

≥47

85

47(55.3)

38(44.7)

0.398

0.445

<47

86

42(48.8)

44(51.2)

Clinical stage

I

21

16(76.2)

5(23.8)

<0.001

<0.001

II

92

53(57.6)

39(42.4)

III

46

20(43.5)

26(56.5)

IV

12

0(0.0)

12(100.0)

T classification

T₁

35

26(74.3)

9(25.7)

<0.001

<0.001

T₂

89

51(57.3)

38(42.7)

T₃

35

11(31.4)

24(68.6)

T₄

12

1(8.3)

11(91.7)

N classification

N₀

70

41(58.6)

29(41.4)

0.419

0.431

N₁

65

33(50.8)

32(49.2)

N₂

27

11(40.7)

16(59.3)

N₃

9

4(44.4)

5(55.6)

M classification

Yes

12

0(0.0)

12(100.0)

<0.001

<0.001

No

159

89(56.0)

70(44.0)

Histological differentiation

Well

9

6(66.7)

3(33.3)

0.005

0.005

Moderate

113

67(59.3)

46(40.7)

Poor

49

16(32.7)

33(67.3)

Expression of ER

0

77

38(49.4)

39(50.6)

0.155

0.165

1

82

41(50.0)

41(50.0)

2

8

7(87.5)

1(12.5)

3

4

3(75.0)

1(25.0)

Expression of PR

0

71

35(49.3)

36(50.7)

0.498

0.527

1

80

41(51.2)

39(48.8)

2

16

11(68.8)

5(31.2)

3

3

1(33.3)

2(66.7)

4

1

1(100.0)

0(0.0)

Expression of ErbB-2

0

42

30(71.4)

12 (28.6)

0.003

0.002

1

52

30(57.7)

22(42.3)

2

38

18(47.4)

20(52.6)

3

30

9(30.0)

21(70.0)

4

9

2(22.2)

7(77.8)